Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study

Michlewska, Sylwia; Malý, Marek; Wójkowska, Dagmara; Karolczak, Kamil; Skiba, Elżbieta; Hołota, Marcin; Kubczak, Małgorzata; Ortega, Paula; Watała, Cezary; Mata, F. Javier de la; Bryszewska, Maria; Йонов, Максим

doi:10.1016/j.ijpharm.2023.122784

Cited by 8 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, ruthenium carbosilane-based and gadolinium dendrimers are of great interest to researchers as drug carriers for delivery of TNBC. Michlewska et al ( Michlewska et al, 2023 ) synthesized a carbosilane metal dendritic polymer (CRD13) and loaded with DOX, 5-fluorouracil (5-Fu), and methotrexate (MTX) drugs to form metal dendrimeric complexes (CRD13@DOX). It was found that CRD13 metal dendrimer complex could encapsulate DOX, 5-Fu, and MTX up to 80%.…”

Section: Novel Nano-drug Delivery Systemsmentioning

confidence: 99%

Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer

Zeng,

Luo,

Gan

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Triple positive breast cancer (TPBC) is one of the most aggressive breast cancer. Due to the unique cell phenotype, aggressiveness, metastatic potential and lack of receptors or targets, chemotherapy is the choice of treatment for TNBC. Doxorubicin (DOX), one of the representative agents of anthracycline chemotherapy, has better efficacy in patients with metastatic TNBC (mTNBC). DOX in anthracycline-based chemotherapy regimens have higher response rates. Nano-drug delivery systems possess unique targeting and ability of co-load, deliver and release chemotherapeutic drugs, active gene fragments and immune enhancing factors to effectively inhibit or kill tumor cells. Therefore, advances in nano-drug delivery systems for DOX therapy have attracted a considerable amount of attention from researchers. In this article, we have reviewed the progress of nano-drug delivery systems (e.g., Nanoparticles, Liposomes, Micelles, Nanogels, Dendrimers, Exosomes, etc.) applied to DOX in the treatment of TNBC. We also summarize the current progress of clinical trials of DOX combined with immune checkpoint inhibitors (ICIS) for the treatment of TNBC. The merits, demerits and future development of nanomedicine delivery systems in the treatment of TNBC are also envisioned, with the aim of providing a new class of safe and efficient thoughts for the treatment of TNBC.

show abstract

Section: Novel Nano-drug Delivery Systemsmentioning

confidence: 99%